Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
Porcine circovirus type 2 (PCV2) ORF2 subunit antigen, Mycoplasma hyopneumoniae J strain inactivated
Intervet International B.V.
QI09AL08
porcine circovirus type 2 ORF2 subunit antigen, Mycoplasma hyopneumoniae inactivated
Pigs (for fattening)
Immunologicals for suidae, Inactivated viral and inactivated bacterial vaccines
For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. To reduce the loss of daily weight gain during the finishing period in face of infections with Mycoplasma hyopneumoniae and/or PCV2 (as observed in field studies)
Revision: 7
Authorised
2014-11-06
18 B. PACKAGE LEAFLET 19 PACKAGE LEAFLET: PORCILIS PCV M HYO EMULSION FOR INJECTION FOR PIGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder and manufacturer responsible for batch release: Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer The NETHERLANDS 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV M Hyo emulsion for injection for pigs 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) 2 ml contains: ACTIVE SUBSTANCES: Porcine circovirus type 2 (PCV2) ORF2 subunit antigen ≥ 2,828 AU 1 _Mycoplasma hyopneumoniae _ J strain inactivated ≥ 2.69 RPU 2 ADJUVANTS: Light mineral oil 0.268 ml Aluminium (as hydroxide) 2.0 mg. 1 Antigenic units as determined in the _in vitro_ potency test (ELISA). 2 Relative potency units defined against a reference vaccine. Homogenous white to nearly white emulsion after shaking. 4. INDICATION(S) For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by _Mycoplasma hyopneumoniae_ infection. To reduce the loss of daily weight gain during the finishing period in face of infections with _Mycoplasma hyopneumoniae_ and/or PCV2 (as observed in field studies). Onset of immunity with single dose vaccination: PCV2: 2 weeks after vaccination. _M. hyopneumoniae:_ 4 weeks after vaccination. Onset of immunity with two dose vaccination: PCV2: 18 days after the first vaccination. _M. hyopneumoniae_ : 3 weeks after the second vaccination. Duration of immunity (both vaccination schedules): PCV2: 22 weeks after (the last) vaccination. _M. hyopneumoniae_ : 21 weeks after (the last) vaccination. 20 5. CONTRAINDICATIONS None. 6. ADVERSE REACTIONS In laboratory studies and field trials: A transient increase in body temperature very commonly occurs on the day of vaccination (mean ±1 °C, in ind Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV M Hyo emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 ml contains: ACTIVE SUBSTANCES: Porcine circovirus type 2 (PCV2) ORF2 subunit antigen ≥ 2,828 AU 1 _Mycoplasma hyopneumoniae_ J strain inactivated ≥ 2.69 RPU 2 ADJUVANTS: Light mineral oil 0.268 ml Aluminium (as hydroxide) 2.0 mg. 1 Antigenic units as determined in the _in vitro_ potency test (ELISA). 2 Relative potency units defined against a reference vaccine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Emulsion for injection. Homogenous white to nearly white emulsion after shaking. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs for fattening 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by _Mycoplasma hyopneumoniae_ infection. To reduce the loss of daily weight gain during the finishing period in face of infections with _Mycoplasma hyopneumoniae_ and/or PCV2 (as observed in field studies). Onset of immunity with single dose vaccination: PCV2: 2 weeks after vaccination _M. hyopneumoniae_ : 4 weeks after vaccination. Onset of immunity with two dose vaccination: PCV2: 18 days after first vaccination _M. hyopneumoniae_ : 3 weeks after the second vaccination. Duration of immunity (both vaccination schedules): PCV2: 22 weeks after (the last) vaccination _M. hyopneumoniae_ : 21 weeks after (the last) vaccination. 4.3 CONTRAINDICATIONS 3 None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Vaccinate healthy animals only. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Not applicable. Special precautions to be taken by the person administering the veterinary medicinal product to animals To the user: This veterinary medicinal product contains mineral oil. Accidental injecti Przeczytaj cały dokument